Peculiarities of immune and cytokine status in patients with brain tumors: literature review
Keywords:
glioma, interleukins, cytokines, immunity, treatmentAbstract
The paper rewiews the last information about the disturbanses of immune and cytokine status in patients with gliomas. Also the analyzed literature dependes acording to the localization and histopatological classification of tumors. This peculiarities have different caracteristics. Some methods of immunotheraphy were discussed.
References
Бережная Н.М. Иммунитет и злокачественные новообразования// Журн. АМН Украины.—1998.—№1.—С.20—31.
Бережная Н.М., Горецкий Б.А. Интерлейкин-2 и злокачественные новообразования.— Киев: Наукова думка, 1992.—С.172.
Бережная Н.М., Чехун В.Ф. Система интерлейкинов и рак.— Киев, 2000.—С.223.
Возианов А.Ф., Бутенко А.К., Зак К.П. Цитокины. Биологические и противоопухолевые свойства.— Киев:Наукова думка,1998.—С.313.
Зозуля Ю.П., Лісяний М.І. Нейрогенний імунодефіцит при вогнищевих ураженнях головного мозку та його клінічне значення// Журн. АМН України.—1998.—Т.4,№1.—С.44—63.
Лисяный Н.И., Мамытов М.М. Изменение иммунологических показателей у больных с опухолями головного мозга// Журн. “Вопросы нейрохирургии им Н.Н.Бурденко”.— 1985.— №6.— С.43—49.
Лисяный Н.И., Маркова О.В., Главацкий А.Я. и др. Содержание FC g RIII-положительных клеток в глиомах разной степени злокачественности// Иммунология. —1999.— №4.— С.56—58.
Малашхия Ю.А., Ломджария Л.Д., Сигуа О.А. Некоторые показатели состояния Т- и В- систем иммунитета при опухолях головного мозга// Иммунология .— 1981.— №2.— С.36—39.
Маркова О.В. Состояние естественной киллерной активности лимфоцитов периферической крови больных с опухолями головного мозга: Автореф. … канд. мед. наук.— Киев, 1990.— С.18.
Свадовский А.И., Бутаков А.А., Переседов В.В. и др. Динамика параметров иммунного статуса больных с глиомами головного мозга при комбинированной терапии с использованием дрожжевого ИЛ-2// Иммунология.— 1996.— № 5.—С.32—36.
Суслов А.П. Макрофаги и противоопухолевый иммунитет// Итоги науки и техники/ Онкология.—1990.—Т.19.—С.167.
Ashkenazi E., Deutch M., Tirosh R. et al. A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: increased level of soluble IL-2 R and reduced protein tyrosine phosphorylation// Neuroimmunomodulation.— 1997.— V.4.—P.49—56.
Brooks W.H., Marford L., Shearer G. et al . Potential exxplanation for the immunodeficiency observed in patients with gliomas. Presented at the 12th international Conference on Brain Tumor Research and Theraphy. Oxford, England, 1997.
Foreman N.K., Rill D.R. , Constan-Smith E. et al. Mechanism of selective killing of neuroblastoma cells and lymphokine activated killer cells. Potential for residual eradication// Br.J. Cancer.—1993.—V.67.—P.933—938.
Fadok V.A., Bratton D., Konowai A. Macrophages that have indested apoptosis cells in vivo inhibit proinflamatory cytokine production through autocrine /paracrine mechanism involving TGFb, PGE2,, and PAF// Clin Invest.—1998.— V.101.—P.890—898.
JamaguchiT., Suzuki Y., Katakura R. et al. Interleukin 15 effectively potentiates the in vitro tumor-specific activity and proliferation of periferal blood gamma delta T-cells, isolated from glioblastoma patients// Cancer immunology, immunotherapy.— 1998.—V47, N 2.—P.97—103.
Jovanovic D.V., Di Battista J.A.et al. IL-7 stimulates the production and expression of proinflammatory cytokines IL-beta and TNF-alpha by humman macrophages// J.Immunol.—1998.— V.160, N7.—P.3513—3521.
Leclerq G., Debacer V., Desmedt M. et al. Differential effects of IL-15 and IL-2 on differentiation of biopotential T-natural killer cells// J.Exp. Med.— 1996.— V.184, N2.—P.325—346.
Mu J., Zou J.P., Yamamoto N. Administration of r IL-12 prevents out-growth of tumor cells methastasizing spontaneously to lung and lymph nodes// Cancer Res.— 1995.— V.95.—P.4404—4408.
Nano R., Capelli E., Civallero M. et al. Activated lymphoid cells in human gliomas : morfofunctional and cytohemical evidence// Anticancer Reseach.— 1997.— V1.—P.107—111.
Ohtsuki T., Micallet M.J., Kohno K. et al. Interleukin-18 enhances Fas-ligand expression and indused apoptosis Fas-expressing human myelomonocytic KG-1 cells// Anticancer Res.— 1997.— V.17.—P.3253—3258.
Oppenheim J., Fujiwara H. The role of cytokines in cancer// Cytocine Growth Factor Rev.— 1996.—V.7.—P.279—288.
Rea I.M., McNerlan S.E., Alexander H.D. CD69, CD25 and HLA-DR activation antigen expression on CD3+ lymphocytes and relationship to serum TN -alpha, IFN-gamma and sIL-2R levels aging//Exp. Gerontol.— 1999.—V.34, N1.—P.79—93.
Romagnani S. Humman TH1- TH2 subsets :” Eppur si muove “// Eur. Cyt. Network.— 1994.— V. 5.—P.7—12.
Salvucci O., Koeb J.P., Dugas B. et al. The induction of nitric oxide by interleukin-12 and tumor necrotic factor-alpha in human natural killer cells: relatioship with the regulation of lytic activity// Blood.— 1998.—V.92, N6.—P.2093—2102.
Thiounn N., Pages S., Flam T. et al. IL-6 is a suvirval prognostic factor in renal cell carcinoma// Immunol. Lett.— 1997.— V.58.—P.121—124.
Tsurushima H., Liu S.Q., Tsuboi K et al. Induction of humman autologus cytotoxic T-lymphocytes against minced tissues of glioblastoma multiforme// J. Neurosurg.— 1996.— V.84.—P.258—263
Urbani F., Maleci A.,La Sala A.et al. Deffective expression of interferon gamma, granulocyte-macrofage colony-stimulating factor, tumor necrosis factor alfa and interleukin6 inactivated periferal blood lymphocytes from glioma patients. Journal of interferon and cytokine research// 1995.—V.15, N5.—P.421—429.
Weller M., Fontana A. The failure of current immunotheraphy for malignant glioma. Tumor-derived TGF b, T-cell apoptosis and the immune privilege of the brain. Brain Research // 1995.— V.21, N2.—P.128—151.
William P. Cytocines: poking holes in the network// Nature.—1992.—V.357.—P.16—27.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2001 Nikolay Lisianyi, Volodymyr Rozumenko, Svitlana Skityak
This work is licensed under a Creative Commons Attribution 4.0 International License.
Ukrainian Neurosurgical Journal abides by the CREATIVE COMMONS copyright rights and permissions for open access journals.
Authors, who are published in this Journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the Journal under the terms of Creative Commons Attribution License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this Journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form of which it has been published by the Journal (for example, to upload the work to the online storage of the Journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this Journal is included.
